Management of patients with patent foramen ovale and cryptogenic stroke: A collaborative, multidisciplinary, position paper

Authors


  • Position statement by the Italian Society of Invasive Cardiology (SICI-GISE); Italian Stroke Association (ISA-AIS); Italian Association of Hospital Neurologists, Neuroradiologists, Neurosurgeons (SNO); Congenital Heart Disease Study Group of Italian Society Of Cardiology; Italian Association Of Hospital Cardiologists (ANMCO); Italian Society Of Pediatric Cardiology (SICP); Italian Society of Cardiovascular Echography (SIEC); Italian Society of Hemostasis and Thrombosis (SISET)

  • Conflict of interest: Massimo Chessa has a proctorship contract with AGA medical, St Jude Medical, Gore, and Cardia. Andrea Donti has a proctorship contract with AGA medical. Achille Gaspardone has a proctorship contract with NMT Medical, Boston, MA (BioSTAR device) and is investigator of BRAVO (A PROSPECTIVE, MULTI-CENTRE, REGISTRY FOR EVALUATION OF THE BioSTAR® SEPTAL REPAIR IMPLANT FOR THE CLOSURE OF PATENT FORAMEN OVALE) Eustaquio Onorato is the principle investigator of INTUIRE (IN-TUNNEL PFO CLOSURE ITALIAN REGISTRY) concerning Coherex FlatStent EF (Coherex Medical) and has proctorship contract with Occlutech Italy. Gianluca Rigatelli has a consultant/proctor contract with St Jude Medical Italy Gennaro Santoro has a proctorship contract with AGA medical. Vittorio Ambrosini received honoraria for being a guest speaker in Occlutech sponsored symposia.

Correspondence to: Christian Pristipino, San Filippo Neri Hospital, Via Alessandro Poerio 140, 00152 Rome, Italy. E-mail: pristipino.c@gmail.com

Abstract

Objectives: To organize a common approach on the management of patent foramen ovale (PFO) and cryptogenic stroke that may be shared by different specialists. Background: The management of PFO related to cryptogenic stroke is controversial, despite an increase in interventional closure procedures. Methods: A consensus statement was developed by approaching Italian national cardiological, neurological, and hematological scientific societies. Task force members were identified by the president and/or the boards of each relevant scientific society or working group, as appropriate. Drafts were outlined by specific task force working groups. To obtain a widespread consensus, these drafts were merged and distributed to the scientific societies for local evaluation and revision by as many experts as possible. The ensuing final draft, merging all the revisions, was reviewed by the task force and finally approved by scientific societies. Results: Definitions of transient ischemic attack and both symptomatic and asymptomatic cryptogenic strokes were specified. A diagnostic workout was identified for patients with candidate event(s) and patient foramen ovale to define the probable pathogenesis of clinical events and to describe individual PFO characteristics. Further recommendations were provided regarding medical and interventional therapy considering individual risk factors of recurrence. Finally, follow-up evaluation was appraised. Conclusions: Available data provided the basis for a shared approach to management of cryptogenic ischemic cerebral events and PFO among different Italian scientific societies. Wider international initiatives on the topic are awaited. © 2013 Wiley Periodicals, Inc.

Ancillary